Isolation and flow cytometric analysis of T-cell-depleted CD34+PBPCs

被引:10
作者
Debelak, J
Shlomchik, MJ
Snyder, EL
Cooper, D
Seropian, S
McGuirk, J
Smith, B
Krause, DS
机构
[1] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA
关键词
D O I
10.1046/j.1537-2995.2000.40121475.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: To extend allogeneic HPC transplantation to a greater range of patients, the use of partially matched related donors is under development. Because of the inherently higher degree of histoincom-patibility in such transplants, there is increased risk of GVHD as well as of graft failure. Ex vivo depletion of donor-derived T-lymphocytes from PBPCs is one of the most effective methods of preventing GVHD. Thus far, individual centers have used custom-developed procedures to deplete the graft of T cells that are responsible for alloreactivity, often employing relatively impure, nonstandardized reagents such as soybean agglutinin and complement. In addition, with improved methods of T-cell depletion, it has been difficult to accurately assess the number of T cells remaining. Because different centers have used different protocols to assay T cells, it has been difficult to reproduce and validate the results between institutions, and this has limited direct comparison of data between centers. STUDY DESIGN AND METHODS: A standardized approach for T-cell depletion was developed by using a Good Manufacturing Practice-manufactured magnetic cell separator (Isolex 300i, Nexell Therapeutics) and commercially available OKT3 antibody. T-cell depletion was performed on PBPCs from six haploidentical donors. RESULTS: CD34+ cell recovery was 47 percent (range, 31-63%) with a median purity of 94 percent (range, 75-99%) and median T-cell log depletion of 4.72 (range, 3.90-5.83). Because this high degree of depletion makes it challenging to accurately quantitate the remaining T cells, two highly sensitive flow cytometric protocols were developed, each of which accurately detects T cells with a sensitivity of 2 per 10,000 (0.02%). The purified CD34+ cells administered to the patients (dose range, 6.13-13.50 x 10(6)/ kg) provided rapid neutrophil and platelet engraftment. CONCLUSION: With the Isolex 300i and a MoAb directed against T cells, a high degree of T-cell depletion is obtained. Sensitive, accurate, and reproducible assays have now been developed for T-cell enumeration in these highly purified cell populations.
引用
收藏
页码:1475 / 1481
页数:7
相关论文
共 20 条
[1]   EFFECT OF HLA COMPATIBILITY ON ENGRAFTMENT OF BONE-MARROW TRANSPLANTS IN PATIENTS WITH LEUKEMIA OR LYMPHOMA [J].
ANASETTI, C ;
AMOS, D ;
BEATTY, PG ;
APPELBAUM, FR ;
BENSINGER, W ;
BUCKNER, CD ;
CLIFT, R ;
DONEY, K ;
MARTIN, PJ ;
MICKELSON, E ;
NISPEROS, B ;
OQUIGLEY, J ;
RAMBERG, R ;
SANDERS, JE ;
STEWART, P ;
STORB, R ;
SULLIVAN, KM ;
WITHERSPOON, RP ;
THOMAS, ED ;
HANSEN, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (04) :197-204
[2]  
ANTIN JH, 1991, BLOOD, V78, P2139
[3]   Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].
Aversa, F ;
Tabilio, A ;
Velardi, A ;
Cunningham, I ;
Terenzi, A ;
Falzetti, F ;
Ruggeri, L ;
Barbabietola, G ;
Aristei, C ;
Latini, P ;
Reisner, Y ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193
[4]   MARROW TRANSPLANTATION FROM RELATED DONORS OTHER THAN HLA-IDENTICAL SIBLINGS [J].
BEATTY, PG ;
CLIFT, RA ;
MICKELSON, EM ;
NISPEROS, BB ;
FLOURNOY, N ;
MARTIN, PJ ;
SANDERS, JE ;
STEWART, P ;
BUCKNER, CD ;
STORB, R ;
THOMAS, ED ;
HANSEN, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) :765-771
[5]  
CHAMPLIN R, 1990, BLOOD, V76, P418
[6]   AUTOLOGOUS PROGENITOR-CELL TRANSPLANTATION - PRIOR EXPOSURE TO STEM CELL-TOXIC DRUGS DETERMINES YIELD AND ENGRAFTMENT OF PERIPHERAL-BLOOD PROGENITOR-CELL BUT NOT OF BONE-MARROW GRAFTS [J].
DREGER, P ;
KLOSS, M ;
PETERSEN, B ;
HAFERLACH, T ;
LOFFLER, H ;
LOEFFLER, M ;
SCHMITZ, N .
BLOOD, 1995, 86 (10) :3970-3978
[7]   EFFECT OF T-CELL DEPLETION AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS ON ENGRAFTMENT, RELAPSE, AND DISEASE-FREE SURVIVAL IN UNRELATED MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA [J].
DROBYSKI, WR ;
ASH, RC ;
CASPER, JT ;
MCAULIFFE, T ;
HOROWITZ, MM ;
LAWTON, C ;
KEEVER, C ;
BAXTERLOWE, LA ;
CAMITTA, B ;
GARBRECHT, F ;
PIETRYGA, D ;
HANSEN, R ;
CHITAMBAR, CR ;
ANDERSON, T ;
FLOMENBERG, N .
BLOOD, 1994, 83 (07) :1980-1987
[8]  
Drobyski WR, 1998, J IMMUNOL, V161, P2610
[9]   BONE-MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA USING A PHENOTYPICALLY HLA-IDENTICAL, SB-COMPATIBLE UNRELATED DONOR [J].
DUQUESNOY, RJ ;
ZEEVI, A ;
MARRARI, M ;
HACKBARTH, S ;
CAMITTA, B .
TRANSPLANTATION, 1983, 35 (06) :566-571
[10]  
GINGRICH RD, 1988, BLOOD, V71, P1375